From Analysis:
Which specific metabolic pathways in APOE4+ microglia are most therapeutically tractable?
While APOE4 disrupts microglial metabolism broadly, the debate didn't identify which specific disrupted pathways offer the best therapeutic targets. This prioritization is needed for focused drug development efforts. Source: Debate session sess_SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 (Analysis: SDA-2026-04-04-gap-neuroinflammation-microglial-20260404)
Enhance MCT1/MCT2 expression to convert metabolic lactate overproduction into alternative fuel source for high-demand states like amyloid clearance
No AI visual card yet
Based on the knowledge gap and the enrichment data showing key microglial functions, here are my novel therapeutic hypotheses:
APOE4 microglia exhibit disrupted mTOR signaling that locks them in a glycolytic state, preventing the metabolic flexibility needed for effective amyloid clearance. Targeting the TREM2-mTOR metabolic checkpoint could restore oxidative metabolism and enhance phagocytic capacity. Small molecule mTOR modulators specifically designed for CNS penetration could selectively reactivate oxidative phosphorylation
I'll critically evaluate each hypothesis, focusing on weaknesses in the evidence and logic, alternative explanations, and missing key considerations.
Specific Weaknesses:
Clinical Validation:
Based on the Theorist's hypotheses, Skeptic's critiques, and Expert's feasibility assessment, here is my synthesis with scored rankings:
No clinical trials data available
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for SLC16A1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
NAD__biosynthesis["NAD+ biosynthesis"] -->|activates| sirtuin_function["sirtuin function"]
TREM2["TREM2"] -->|mediates| amyloid_clearance["amyloid clearance"]
APOE4["APOE4"] -.->|inhibits| NAMPT["NAMPT"]
APOE4_1["APOE4"] -->|activates| MTOR_signaling["MTOR signaling"]
MTOR["MTOR"] -->|regulates| metabolic_flexibility["metabolic flexibility"]
APOE4_2["APOE4"] -->|causes| lipid_droplet_formation["lipid droplet formation"]
DGAT1["DGAT1"] -->|catalyzes| lipid_droplet_formation_3["lipid droplet formation"]
APOE4_4["APOE4"] -->|disrupts| mitochondrial_ER_contacts["mitochondrial-ER contacts"]
VDAC1["VDAC1"] -->|regulates| mitochondrial_ER_contacts_5["mitochondrial-ER contacts"]
SLC16A1["SLC16A1"] -->|mediates| lactate_transport["lactate transport"]
SMPD1["SMPD1"] -->|regulates| sphingolipid_metabolism["sphingolipid metabolism"]
mTOR_modulators["mTOR modulators"] -->|enhances| oxidative_phosphorylation["oxidative phosphorylation"]
style NAD__biosynthesis fill:#81c784,stroke:#333,color:#000
style sirtuin_function fill:#4fc3f7,stroke:#333,color:#000
style TREM2 fill:#4fc3f7,stroke:#333,color:#000
style amyloid_clearance fill:#4fc3f7,stroke:#333,color:#000
style APOE4 fill:#ce93d8,stroke:#333,color:#000
style NAMPT fill:#ce93d8,stroke:#333,color:#000
style APOE4_1 fill:#ce93d8,stroke:#333,color:#000
style MTOR_signaling fill:#81c784,stroke:#333,color:#000
style MTOR fill:#4fc3f7,stroke:#333,color:#000
style metabolic_flexibility fill:#4fc3f7,stroke:#333,color:#000
style APOE4_2 fill:#ce93d8,stroke:#333,color:#000
style lipid_droplet_formation fill:#4fc3f7,stroke:#333,color:#000
style DGAT1 fill:#4fc3f7,stroke:#333,color:#000
style lipid_droplet_formation_3 fill:#4fc3f7,stroke:#333,color:#000
style APOE4_4 fill:#ce93d8,stroke:#333,color:#000
style mitochondrial_ER_contacts fill:#4fc3f7,stroke:#333,color:#000
style VDAC1 fill:#4fc3f7,stroke:#333,color:#000
style mitochondrial_ER_contacts_5 fill:#4fc3f7,stroke:#333,color:#000
style SLC16A1 fill:#4fc3f7,stroke:#333,color:#000
style lactate_transport fill:#4fc3f7,stroke:#333,color:#000
style SMPD1 fill:#4fc3f7,stroke:#333,color:#000
style sphingolipid_metabolism fill:#81c784,stroke:#333,color:#000
style mTOR_modulators fill:#4fc3f7,stroke:#333,color:#000
style oxidative_phosphorylation fill:#4fc3f7,stroke:#333,color:#000
neurodegeneration | 2026-04-08 | completed
No comments yet. Be the first to comment!